Shenar Dinkha

Sirolimus and ruxolitinib in progressive Bronchiolitis Obliterans Syndrome due to chronic Graft-Versus-Host disease

Bronchiolitis obliterans syndrome (BOS) is a pulmonary manifestation of chronic graft-versus-host disease (GVHD) that can occur as a complication in up to 14% of hematopoietic stem cell transplantation (HSCT) recipients. First-line therapy for BOS includes inhaled fluticasone, az...